Showing 6251-6260 of 7027 results for "".
- Pfizer-AGN Deal Offhttps://practicaldermatology.com/news/all-eyes-on-pfizer-agn-deal-is-it-doa/2458617/UPDATE: Allergan and Pfizer have mutually agreed to end their merger agreement, according to a statement from Allergan. Pfizer has agreed to pay Allergan $150 million in reimbursement for expenses associated with the transaction. Dublin-based Allergan reiterates in the statement its growth opport
- Galderma, Mentor Worldwide, LLC Set to Collaboratehttps://practicaldermatology.com/news/galderma-mentor-worldwide-llc-set-to-collaborate/2458623/Galderma and Mentor Worldwide LLC, are joining forces to increase awareness and provide a broader range of offerings to healthcare providers and patients seeking aesthetic injectable treatments and breast enhancement. Data shows up to 33% of women
- Rosacea Awareness Month Highlights Potential Increased Health Riskshttps://practicaldermatology.com/news/rosacea-awareness-month-highlights-potential-increased-health-risks/2458624/New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the
- Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe ADhttps://practicaldermatology.com/news/next-stop-fda-approval-dupilumab-improves-symptoms-in-moderate-to-severe-ad/2458625/Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) granted dupilumab Breakthrough Therapy designation in AD in November 2014. U.S. regulatory
- North America's Scar Treatment Poised for Growth Spurt by 2022https://practicaldermatology.com/news/north-america-scar-treatment-market-set-to-grow-by-2022/2458629/Scar treatment will be a hot growth area in coming years, according to a new report by Persistence Market Research. The report cites a rising incidence of burn and trauma cases and an increasing preval
- More Than 1,000 Patients Join Corrona Psoriasis Registryhttps://practicaldermatology.com/news/more-than-1000-patients-join-corrona-psoriasis-registry/2458631/The Corrona Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, now includes more than 1,000 patients from 100 sites. Dermatologists assess registry pa
- FDA Greenlights Taltz for Psoriasishttps://practicaldermatology.com/news/fda-greenlights-taltz-for-psoriasis/2458635/The U.S. Food and Drug Administration approved the IL-17A blocker Taltz (ixekizumab) for adults with moderate-to-severe plaque psoriasis. Taltz is marketed by Indianapolis, Indiana-based Eli Lilly and Company. Given via
- Many Parents are Concerned About Fake Online MD Reviewshttps://practicaldermatology.com/news/many-parents-are-concerned-about-fake-online-md-reviews/2458637/More than two-thirds of parents believe some online doctor reviews are fake, while slightly fewer say there are not enough ratings to make a good decision, according a report from C.S. Mott Children’s Hospital National Poll on Children’s Health. More than half of p
- FDA Approves PMA Supplement for MelaFind from STRATA Scienceshttps://practicaldermatology.com/news/fda-accepts-pma-for-melafind-from-strata-sciences/2458644/The FDA has approved STRATA Skin Sciences, Inc.’s PMA supplement for the MelaFind System. The FDA approved MelaFind’s use of the “classifier score data”, a quantitative result derived by the MelaFind System that can be beneficially used in conjunction with the previously a
- InfoRx App from Vivacare Enables Dermatologists to Deliver Personalized Patient Education Resourceshttps://practicaldermatology.com/news/inforx-app-from-vivacare-enables-dermatologists-to-deliver-personalized-patient-education-resources/2458651/Vivacare announced the release of its InfoRx mobile app that enables dermatologists to deliver personalized patient handouts, videos and other skin care resources into the hands of their patients and family members. The service is available to U.S.-based dermato